 Home > Active Ingredient News > Antitumor Therapy > J Immunother Cancer: Antibiotics have a significant negative effect on the prognosis of NSCLC patients treated with pembrolizumab!

J Immunother Cancer: Antibiotics have a significant negative effect on the prognosis of NSCLC patients treated with pembrolizumab!

 Last Update: 2021-04-16
 Source: Internet
 Author: User

Tags

paclitaxel adverse effects

liquid biopsy cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In unselected patients with non-small cell lung cancer ( NSCLC ) , some concomitant drugs , including antibiotics (ATB), are related to poor survival of immune checkpoint inhibitor (ICI) treatment, and the correlation is reproducible .

An article published recently in " J Immunother Cancer " of " Journal of Cancer Immunotherapy " outlines a large-scale study of patients with metastatic NSCLC who received first-line pembrolizumab monotherapy with PD-L1 expression of ≥50%.

J Immunother Cancer J Immunother Cancer

The pembrolizumab and chemotherapy cohorts included 950 and 595 patients, respectively.

Metformin

Overall survival analysis

In multivariate analysis, ATB can be used as a strong predictor of poor overall survival (OS) and progression-free survival (PFS) in the pembrolizumab group (HR is 1.

ATB can be used as a strong predictor of poor overall survival (OS) and progression-free survival (PFS) in the pembrolizumab group (HR 1.

Progression-free survival analysis

Corticosteroids after pembrolizumab treatment or chemotherapy were associated with shorter PFS (HR 1.

In summary, this study proved that ATB has a significant negative effect on the prognosis of NSCLC patients with pembrolizumab monotherapy , but it has no significant effect on chemotherapy, which further proves the potential immunomodulatory effect between them.

ATB has a significant negative effect on the prognosis of NSCLC patients with pembrolizumab monotherapy.

Original source:

Cortellini A, Di Maio M, Nigro O, et al bmj.

bmj.
com/content/9/4/e002421" target="_blank" rel="noopener">Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.